Takeda teams up with Alnylam in potential $1B deal

Takeda Pharmaceutical Co. Ltd. has entered into a licensing agreement with Alnylam Pharmaceuticals to secure rights to RNA interference technology. Alnylam, which said it may receive as much as $1 billion from the deal, will work with Takeda for five years to develop RNAi-based therapies, specifically to treat cancer and metabolic diseases.

View Full Article in:

Boston Herald · Bloomberg · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Counsel, Regulatory (FDA)
CareFusion
San Diego , CA
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations